Cargando…

Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway

The complement system comprises the frontline of the innate immune system. Triggered by pathogenic surface patterns in different pathways, the cascade concludes with the formation of a membrane attack complex (MAC; complement components C5b to C9) and C5a, a potent anaphylatoxin that elicits various...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anliker-Ort, Marion, Dingemanse, Jasper, van den Anker, John, Kaufmann, Priska
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758461/ https://www.ncbi.nlm.nih.gov/pubmed/33362783 http://dx.doi.org/10.3389/fimmu.2020.599417

Ejemplares similares

Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT‐1014‐6470 in vitro and in vivo
por: Anliker‐Ort, Marion, et al.
Publicado: (2023)

Modeling time‐delayed concentration‐QT effects with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a(1) receptor) antagonist
por: Anliker‐Ort, Marion, et al.
Publicado: (2023)

Weak Expression of Terminal Complement in Active Antibody-Mediated Rejection of the Kidney
por: Tiller, Gesa, et al.
Publicado: (2022)

Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients
por: Harder, Markus J., et al.
Publicado: (2019)

Effect of nivasorexant (ACT‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects
por: Berger, Benjamin, et al.
Publicado: (2023)

The Alternative Complement Pathway Is Activated Without a Corresponding Terminal Pathway Activation in Patients With Heart Failure
por: Holt, Margrethe Flesvig, et al.
Publicado: (2021)

A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the Staphylococcus aureus SSL7 Protein
por: Yatime, Laure, et al.
Publicado: (2018)

Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation
por: Tang, Guo-Qing, et al.
Publicado: (2023)

Upregulation of Early and Downregulation of Terminal Pathway Complement Genes in Subcutaneous Adipose Tissue and Adipocytes in Acquired Obesity
por: Kaye, Sanna, et al.
Publicado: (2017)

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag
por: Kaufmann, Priska, et al.
Publicado: (2015)

Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway
por: Barratt, Jonathan, et al.
Publicado: (2021)

Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation
por: Tang, Guo-Qing, et al.
Publicado: (2023)

Therapeutic Modulation of the Complement System in Kidney Transplantation: Clinical Indications and Emerging Drug Leads
por: Tatapudi, Vasishta S., et al.
Publicado: (2019)

The Complement C3a and C3a Receptor Pathway in Kidney Diseases
por: Gao, Shuang, et al.
Publicado: (2020)

Insights Into Enhanced Complement Activation by Structures of Properdin and Its Complex With the C-Terminal Domain of C3b
por: van den Bos, Ramon M., et al.
Publicado: (2019)

A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist
por: Hoch, Matthias, et al.
Publicado: (2014)

Elevated Terminal C5b-9 Complement Complex 10 Weeks Post Kidney Transplantation Was Associated With Reduced Long-Term Patient and Kidney Graft Survival
por: Witczak, Bartlomiej J., et al.
Publicado: (2021)

Complement Activation in Inflammatory Skin Diseases
por: Giang, Jenny, et al.
Publicado: (2018)

The Complement System and ANCA Associated Vasculitis in the Era of Anti-Complement Drugs
por: Kimoto, Yasutaka, et al.
Publicado: (2022)

Complement-targeted therapies in kidney transplantation—insights from preclinical studies
por: Anwar, Imran J., et al.
Publicado: (2022)

Complement Activation in Kidneys of Patients With COVID-19
por: Pfister, Frederick, et al.
Publicado: (2021)

The Complement System in Metabolic-Associated Kidney Diseases
por: Xu, Ziyu, et al.
Publicado: (2022)

Editorial: Updates on the complement system in kidney diseases
por: Bulla, Roberta, et al.
Publicado: (2023)

Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer
por: Kleczko, Emily K., et al.
Publicado: (2019)

Staphylococcal Complement Evasion Protein Sbi Stabilises C3d Dimers by Inducing an N-Terminal Helix Swap
por: Dunphy, Rhys W., et al.
Publicado: (2022)

The role of the complement system in kidney glomerular capillary thrombosis
por: Yoshida, Yoko, et al.
Publicado: (2022)

A New Tool for Complement Research: In vitro Reconstituted Human Classical Complement Pathway
por: Mutti, Michele, et al.
Publicado: (2018)

Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases
por: Dobó, József, et al.
Publicado: (2018)

Editorial: Antimicrobial Peptides and Complement – Maximising the Inflammatory Response
por: Stover, Cordula M.
Publicado: (2015)

Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction
por: Karasu, Ebru, et al.
Publicado: (2019)

Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases
por: Michels, Marloes A. H. M., et al.
Publicado: (2018)

Genetic investigation of Nordic patients with complement-mediated kidney diseases
por: Rydberg, Viktor, et al.
Publicado: (2023)

Disease-associated N-terminal Complement Factor H Mutations Perturb Cofactor and Decay-accelerating Activities
por: Pechtl, Isabell C., et al.
Publicado: (2011)

Functional Characterization of the Disease-Associated N-Terminal Complement Factor H Mutation W198R
por: Cserhalmi, Marcell, et al.
Publicado: (2017)

Increased plasma level of terminal complement complex in AMD patients: potential functional consequences for RPE cells
por: Busch, Catharina, et al.
Publicado: (2023)

Corrigendum: Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction
por: Karasu, Ebru, et al.
Publicado: (2019)

Key Components of the Complement Lectin Pathway Are Not Only Required for the Development of Inflammatory Arthritis but Also Regulate the Transcription of Factor D
por: Holers, V. Michael, et al.
Publicado: (2020)

C-Reactive Protein Binds to Cholesterol Crystals and Co-Localizes with the Terminal Complement Complex in Human Atherosclerotic Plaques
por: Pilely, Katrine, et al.
Publicado: (2017)

Complement Alternative and Mannose-Binding Lectin Pathway Activation Is Associated With COVID-19 Mortality
por: Defendi, Federica, et al.
Publicado: (2021)

Integrative Omics Analysis Unravels Microvascular Inflammation-Related Pathways in Kidney Allograft Biopsies
por: Tinel, Claire, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_12387ctvoc0b7rthe7dal9s9mk